DNA Vaccines

HOME > R&D > DNA Vaccines
Comparison with Traditional vaccines

  Traditional vaccines (Old paradigm) DNA vaccines (New paradigm)
Safety Attenuated or killed infectious pathogens Injection of genes of a representative antigen from infectious pathogens
There are safety concerns regarding vaccines for highly infectious disease. Can be used for highly-infectious diseases such as AIDS, pandemic influenza, and malaria without concern of pathogenicity
Mechanism of Immune Response/ Vaccine type Primarily forming antibodies. / preventive vaccines In addition to antibody formation, it induces a T-cell-mediated immune response.
/ vaccines for prevention and treatment
Manufacturing/Storage Must be stored in a refrigerator Can be stored at room temperature for long-term periods
Long manufacturing period (6 months) Short manufacturing period (1 month)
Indication Primarily prevention of infectious diseases Prevention and treatment of infectious diseases and cancer/ auto-immune diseases
History of DNA vaccine development
Early 1990s Potency and potentiality of DNA vaccines confirmed in experimental animals
1994 First clinical study of the 1st generation DNA vaccines for patients with AIDS
2005 Three DNA vaccines for veterinary use launched
2006 2nd generation DNA vaccine development started using antigen
expression optimization technology and in vivo delivery via electroporation
→ interest from health authorities and global pharmaceutical companies.
2014 First positive Phase II study results of DNA vaccine
VGX-3100, Therapeutic DNA vaccine for cervical dysplasia
Presented in July 2014 at DNA Vaccines, San Diego CA USA
→ POC validation of DNA vaccines completed in human
Market size of existing vaccine

The value of the global vaccine market was US$31.7 billion in 2011 and is estimated to reach
US$56.7 billion by 2017 with a mean annual growth rate of 11.5%.